A Phase I-II Pilot Study to Assess the Safety and Efficacy of Combined Administration With Pegylated Interferon-alpha2a and the Histone Deacetylase Inhibitor (HDACi) Panobinostat for Reducing the Residual Reservoir of HIV-1 Infected Cells in cART-Treated HIV-1 Positive Individuals

Trial Profile

A Phase I-II Pilot Study to Assess the Safety and Efficacy of Combined Administration With Pegylated Interferon-alpha2a and the Histone Deacetylase Inhibitor (HDACi) Panobinostat for Reducing the Residual Reservoir of HIV-1 Infected Cells in cART-Treated HIV-1 Positive Individuals

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Panobinostat (Primary) ; Peginterferon alfa-2a
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms ACTIVATE
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 03 May 2016 Status changed from not yet recruiting to recruiting.
    • 29 Apr 2016 Planned initiation date changed from 1 Mar 2016 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top